IP Library › Granted Patent US 8,033,284
Granted Patent B2
US 8,033,284 · App. 11/329,705 · Granted Oct 11, 2011

Therapeutic laser treatment

Assignee: Curaelase, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,033,284
App. No.
11/329,705
Granted
Oct 11, 2011
Kind
B2
Abstract

A method for treating selected tissue, including exposing the selected bone or tissue to laser light having a wavelength between approximately 600 and 1400 nm, and maintaining such exposure of the selected tissue or bone to the laser light for a period of time sufficient to deliver a laser light dosage of at least 7 Joules/cm 2 per treatment and maintaining such exposure for a period of time sufficient to deliver a laser light dosage of at least 1500 Joules per treatment within a 24 hour period of time. The method also includes upcollimating the laser light such that the laser delivers to the selected tissue a substantially coherent beam of laser light having a cross-sectional area of at least 2 cm 2 , and, further, delivering the laser light to a depth of at least 5 mm in the selected tissue.

Claims (36)

1. A method for treating selected tissue physiologically linked to trigeminal neuralgia, comprising:

providing a laser light source that delivers a beam of monochromatic coherent light at about 1064 nm;

providing an aiming laser for aiming said beam of monochromatic coherent laser light;

aiming said aiming laser at the tissue to define a target in the tissue;

collimating said beam of monochromatic coherent laser light into a beam of collimated monochromatic coherent light having a cross-sectional area of at least ten cm 2 ; and

exposing an area of at least ten cm 2 of said target in the tissue to a depth of at least five millimeters in the tissue with said beam of collimated monochromatic coherent light at a power density of approximately 500 mW/cm 2 for a time sufficient to deliver at least 40 Joules/cm 2 and at least 1,500 total Joules to the tissue per treatment, to thereby treat said trigeminal neuralgia.

2. The method of claim 1 , further comprising:

providing a probe connected to said laser light source that outputs said beam of collimated monochromatic coherent light; and

wherein said exposing of said target in the tissue with said collimated monochromatic coherent light includes pressing said probe against the skin of a patient.

3. A method for treating selected neurological tissue, comprising:

providing a laser light source that delivers a beam of monochromatic coherent light at about 1064 nm;

providing an aiming laser for aiming said beam of monochromatic coherent laser light;

aiming said aiming laser at the tissue to define a target in the tissue;

collimating said beam of monochromatic coherent laser light into a beam of collimated monochromatic coherent light having a cross-sectional area of at least ten cm 2 ; and

exposing an area of at least ten cm 2 of said target in the tissue to a depth of at least five millimeters in the tissue with said beam of collimated monochromatic coherent light at a power density of approximately 500 mW/cm 2 for a time sufficient to deliver at least 40 Joules/cm 2 and at least 1,500 total Joules to the tissue per treatment, to thereby treat said neurological tissue.

4. The method of claim 3 , further comprising:

providing a probe connected to said laser light source that outputs said beam of collimated monochromatic coherent light; and

wherein said exposing of said target in the tissue with said collimated monochromatic coherent light includes pressing said probe against the skin of a patient.

5. A method for treating selected tissue physiologically linked to migraine headaches, comprising:

providing a laser light source that delivers a beam of monochromatic coherent light at about 1064 nm;

providing an aiming laser for aiming said beam of monochromatic coherent laser light;

aiming said aiming laser at the tissue to define a target in the tissue;

collimating said beam of monochromatic coherent laser light into a beam of collimated monochromatic coherent light having a cross-sectional area of at least ten cm 2 ; and

exposing an area of at least ten cm 2 of said target in the tissue to a depth of at least five millimeters in the tissue with said beam of collimated monochromatic coherent light at a power density of approximately 500 mW/cm 2 for a time sufficient to deliver at least 40 Joules/cm 2 and at least 1,500 total Joules to the tissue per treatment, to thereby treat said migraine headaches.

6. A method for treating selected tissue physiologically linked to reflex sympathetic dystrophy, comprising:

providing a laser light source that delivers a beam of monochromatic coherent light at about 1064 nm;

providing an aiming laser for aiming said beam of monochromatic coherent laser light;

aiming said aiming laser at the tissue to define a target in the tissue;

collimating said beam of monochromatic coherent laser light into a beam of collimated monochromatic coherent light having a cross-sectional area of at least ten cm 2 ; and

exposing an area of at least ten cm 2 of said target in the tissue to a depth of at least five millimeters in the tissue with said beam of collimated monochromatic coherent light at a power density of approximately 500 mW/cm 2 for a time sufficient to deliver at least 40 Joules/cm 2 and at least 1,500 total Joules to the tissue per treatment, to thereby treat said reflex sympathetic dystrophy.

7. A method for treating selected tissue physiologically linked to peripheral neuropathy, comprising:

providing a laser light source that delivers a beam of monochromatic coherent light at about 1064 nm;

providing an aiming laser for aiming said beam of monochromatic coherent laser light;

aiming said aiming laser at the tissue to define a target in the tissue;

collimating said beam of monochromatic coherent laser light into a beam of collimated monochromatic coherent light having a cross-sectional area of at least ten cm 2 ; and

exposing an area of at least ten cm 2 of said target in the tissue to a depth of at least five millimeters in the tissue with said beam of collimated monochromatic coherent light at a power density of approximately 500 mW/cm 2 for a time sufficient to deliver at least 40 Joules/cm 2 and at least 1,500 total Joules to the tissue per treatment, to thereby treat said peripheral neuropathy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2006
From: PORTER, ROGER D.; MCARTHUR, FRANK G.
To: CURAELASE, INC.
Reel/Frame 018188/0070 →
Continuity (1)
Related Publication 20070162093A1 · Jul 12, 2007